Loading
Companies extend monopolies on cancer drugs with dozens of minor patents and deals that pay generic makers to stay out. Closing these loopholes would bring cheaper versions years earlier.
Analyses of imatinib, lenalidomide and other oncology blockbusters show effective exclusivity extended by years through secondary patents on salts, formulations and dosing and through settlements delaying generic entry. India's Section 3(d) restricts secondary patents; the EU and US have sanctioned some pay-for-delay deals. The proposal is a coordinated set of reforms: a higher inventive-step bar for secondary pharmaceutical patents, presumptive illegality of reverse-payment settlements, and a public database of patent expiry dates per oncology product so generic entry can be planned.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Prices and value.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Prices and value.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Prices and value.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Prices and value.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Prices and value.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Prices and value.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Prices and value.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Prices and value.